Your browser is no longer supported. Please, upgrade your browser.
Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own1.10% Shs Outstand135.94M Perf Week8.16%
Market Cap4.26B Forward P/E19.30 EPS next Y1.61 Insider Trans-8.26% Shs Float131.67M Perf Month20.82%
Income-39.70M PEG- EPS next Q0.20 Inst Own- Short Float11.11% Perf Quarter11.03%
Sales180.50M P/S23.60 EPS this Y10.50% Inst Trans-0.72% Short Ratio13.71 Perf Half Y33.36%
Book/sh0.78 P/B39.87 EPS next Y133.82% ROA-8.10% Target Price32.73 Perf Year108.31%
Cash/sh2.81 P/C11.05 EPS next 5Y58.00% ROE-31.70% 52W Range12.71 - 31.64 Perf YTD75.41%
Dividend- P/FCF- EPS past 5Y2.10% ROI-13.70% 52W High-1.71% Beta1.62
Dividend %- Quick Ratio17.30 Sales past 5Y21.10% Gross Margin72.00% 52W Low144.69% ATR0.98
Employees132 Current Ratio19.20 Sales Q/Q41.20% Oper. Margin-16.80% RSI (14)74.20 Volatility3.41% 3.20%
OptionableYes Debt/Eq3.69 EPS Q/Q285.90% Profit Margin-22.00% Rel Volume1.10 Prev Close31.09
ShortableYes LT Debt/Eq3.69 EarningsNov 02 AMC Payout- Avg Volume1.07M Price31.10
Recom2.30 SMA2011.51% SMA5011.70% SMA20031.14% Volume1,178,896 Change0.03%
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Oct-22-20 07:30PM  
Oct-21-20 08:38AM  
Oct-20-20 03:16PM  
Oct-06-20 02:14AM  
Sep-28-20 10:40AM  
Sep-17-20 08:00AM  
Sep-10-20 08:01AM  
Sep-09-20 11:30AM  
08:01AM  
Sep-02-20 04:01PM  
Aug-11-20 11:18AM  
09:00AM  
Aug-10-20 05:25PM  
04:01PM  
Aug-04-20 04:05PM  
Aug-03-20 12:31PM  
Jul-29-20 04:05PM  
Jul-28-20 12:32PM  
Jul-23-20 09:49AM  
Jul-17-20 01:30PM  
Jul-09-20 02:46PM  
Jul-01-20 07:20PM  
Jun-29-20 12:54PM  
Jun-22-20 08:00AM  
Jun-19-20 08:32AM  
Jun-17-20 05:08PM  
Jun-16-20 10:01AM  
Jun-13-20 07:09AM  
Jun-10-20 11:30AM  
Jun-04-20 12:35PM  
May-29-20 10:28AM  
May-28-20 08:01AM  
May-20-20 08:32AM  
May-19-20 08:37AM  
May-15-20 11:25AM  
May-14-20 04:01PM  
May-13-20 03:18AM  
May-12-20 09:52AM  
04:31AM  
May-11-20 06:35PM  
04:01PM  
11:50AM  
May-08-20 10:34AM  
May-07-20 08:01AM  
May-01-20 03:16PM  
Apr-30-20 04:56PM  
Apr-28-20 05:05PM  
12:33PM  
Apr-26-20 09:40PM  
Apr-13-20 08:44AM  
Apr-03-20 08:00AM  
Mar-29-20 05:44PM  
Mar-25-20 11:30AM  
Mar-19-20 10:30AM  
Mar-05-20 06:36PM  
Feb-28-20 08:39AM  
Feb-27-20 07:37AM  
Feb-26-20 04:01PM  
Feb-25-20 10:05AM  
01:20AM  
Feb-24-20 05:45PM  
04:02PM  
04:01PM  
Feb-17-20 12:30PM  
Feb-10-20 04:01PM  
Feb-06-20 08:25AM  
Jan-14-20 08:00AM  
Jan-03-20 08:00AM  
Dec-12-19 11:30AM  
02:00AM  
Dec-06-19 10:02AM  
Nov-20-19 05:28PM  
Nov-15-19 10:09AM  
Nov-14-19 08:27AM  
Nov-13-19 10:57PM  
09:06AM  
Nov-12-19 05:45PM  
04:30PM  
04:10PM  
04:01PM  
Nov-07-19 12:56PM  
Nov-05-19 10:32AM  
Nov-04-19 09:56AM  
07:00AM  
07:00AM  
Nov-01-19 09:05AM  
Oct-23-19 01:30PM  
Oct-21-19 08:00AM  
Oct-02-19 09:14AM  
Sep-23-19 08:00AM  
Sep-13-19 09:44PM  
05:27PM  
01:00AM  
Sep-02-19 10:48AM  
Aug-26-19 08:00AM  
Aug-08-19 10:58AM  
Aug-06-19 06:15PM  
04:01PM  
12:20PM  
Jul-30-19 10:38AM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaBarre Michael J.SVP, Chief Technical OfficerOct 20Sale30.4312,000365,148146,800Oct 20 04:53 PM
LaBarre Michael J.SVP, Chief Technical OfficerSep 21Sale26.9112,000322,884158,800Sep 21 07:30 PM
MATSUI CONNIEDirectorSep 11Sale27.0632,000865,792216,753Sep 14 05:33 PM
Matsuda MasaruSVP, General CounselSep 04Option Exercise0.006,884013,822Sep 04 06:13 PM
LaBarre Michael J.SVP, Chief Technical OfficerAug 20Sale28.3012,000339,564170,800Aug 20 04:21 PM
Daly James MDirectorAug 13Sale29.1234,337999,89331,365Aug 13 06:43 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 20Sale29.0112,000348,072182,800Jul 20 06:33 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 22Option Exercise7.1418,613132,897194,800May 22 06:39 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Option Exercise7.1421,387152,703197,574May 21 04:11 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Sale23.8021,387509,075176,187May 21 04:11 PM
Kelley Kenneth JDirectorMar 19Buy14.2352,629748,697277,553Mar 19 07:28 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030179,231Feb 24 08:04 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,3920120,675Feb 24 08:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540510,033Feb 24 08:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7720172,423Feb 18 04:16 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,8090111,983Feb 18 04:15 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300484,923Feb 18 04:14 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,13008,619Feb 13 06:41 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,376Feb 13 06:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 12Option Exercise0.0011,2620108,068Feb 13 06:38 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950472,452Feb 13 06:24 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 03Option Exercise0.0011,5590165,782Feb 04 04:24 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,1190105,081Feb 04 04:21 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870459,567Feb 04 04:18 PM
CHRS Coherus BioSciences, Inc. daily Stock Chart
CHRS [NASD]
Coherus BioSciences, Inc.
Index- P/E7.74 EPS (ttm)2.27 Insider Own0.50% Shs Outstand71.10M Perf Week-3.09%
Market Cap1.21B Forward P/E13.30 EPS next Y1.32 Insider Trans-46.17% Shs Float63.64M Perf Month-2.22%
Income180.90M PEG3.52 EPS next Q0.41 Inst Own- Short Float27.91% Perf Quarter-7.03%
Sales487.40M P/S2.49 EPS this Y138.10% Inst Trans5.24% Short Ratio18.47 Perf Half Y-0.40%
Book/sh3.00 P/B5.86 EPS next Y-31.09% ROA36.90% Target Price30.22 Perf Year3.96%
Cash/sh6.61 P/C2.66 EPS next 5Y2.20% ROE136.00% 52W Range10.86 - 23.03 Perf YTD-2.30%
Dividend- P/FCF8.63 EPS past 5Y16.20% ROI37.00% 52W High-23.62% Beta1.66
Dividend %- Quick Ratio5.00 Sales past 5Y62.80% Gross Margin93.60% 52W Low61.95% ATR0.72
Employees306 Current Ratio5.20 Sales Q/Q62.70% Oper. Margin41.70% RSI (14)46.27 Volatility4.68% 3.88%
OptionableYes Debt/Eq1.89 EPS Q/Q106.10% Profit Margin37.10% Rel Volume0.76 Prev Close17.00
ShortableYes LT Debt/Eq1.89 EarningsNov 05 AMC Payout0.00% Avg Volume961.75K Price17.59
Recom1.90 SMA20-1.88% SMA50-5.11% SMA200-2.18% Volume732,910 Change3.47%
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Mar-09-18Reiterated Maxim Group Buy $20 → $15
Aug-08-17Reiterated JP Morgan Overweight $32 → $25
Jun-13-17Reiterated Maxim Group Buy $44 → $40
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
Oct-22-20 04:15PM  
Oct-16-20 09:30AM  
Oct-05-20 09:44AM  
Sep-28-20 05:23PM  
Sep-18-20 11:02AM  
Sep-13-20 10:10AM  
Aug-21-20 09:30AM  
Aug-11-20 03:45PM  
Aug-06-20 08:10PM  
04:02PM  
Aug-03-20 04:48PM  
Jul-30-20 12:33PM  
Jul-17-20 09:30AM  
Jul-16-20 09:30AM  
Jul-14-20 03:49PM  
Jul-09-20 08:56PM  
Jun-19-20 09:30AM  
Jun-15-20 04:05PM  
Jun-12-20 08:31AM  
Jun-03-20 03:35AM  
May-26-20 06:16PM  
12:53PM  
May-21-20 12:47PM  
May-13-20 07:08PM  
May-10-20 10:47PM  
08:59AM  
May-08-20 05:30PM  
01:05PM  
May-07-20 04:08PM  
May-04-20 09:30AM  
Apr-30-20 12:34PM  
Apr-22-20 09:30AM  
Apr-21-20 05:39PM  
Apr-16-20 07:27AM  
Apr-15-20 12:05AM  
Apr-14-20 07:52AM  
Apr-13-20 09:23AM  
Apr-08-20 10:49AM  
Apr-07-20 06:59AM  
Mar-26-20 08:34AM  
Mar-20-20 09:30AM  
Mar-14-20 02:43AM  
Mar-09-20 05:01AM  
Mar-05-20 04:09PM  
07:00AM  
Feb-29-20 08:54AM  
Feb-27-20 04:01PM  
Feb-26-20 09:30AM  
Feb-24-20 09:43AM  
Feb-20-20 11:19AM  
Feb-11-20 11:30AM  
Feb-07-20 12:00PM  
Feb-06-20 09:34AM  
Jan-23-20 11:30AM  
Jan-17-20 08:16AM  
Jan-13-20 08:30AM  
Jan-08-20 08:53AM  
Jan-07-20 11:30AM  
09:59AM  
Jan-03-20 09:55AM  
09:30AM  
09:01AM  
Dec-30-19 09:44AM  
Dec-19-19 11:30AM  
Dec-16-19 09:34AM  
Dec-07-19 12:25PM  
Dec-03-19 08:51AM  
Nov-26-19 11:27AM  
Nov-19-19 09:36AM  
Nov-15-19 11:17PM  
10:08AM  
Nov-12-19 09:30AM  
08:18AM  
Nov-11-19 09:28AM  
Nov-08-19 09:30AM  
Nov-06-19 06:15PM  
04:01PM  
04:01PM  
Oct-29-19 03:16PM  
Oct-28-19 11:18AM  
Oct-26-19 01:22PM  
Oct-21-19 07:44AM  
Oct-18-19 09:30AM  
Oct-15-19 09:30AM  
Sep-25-19 04:37PM  
Sep-20-19 09:30AM  
Sep-10-19 03:18PM  
09:00AM  
Sep-04-19 11:51AM  
Aug-28-19 04:05PM  
Aug-22-19 09:30AM  
09:11AM  
Aug-21-19 09:30AM  
Aug-01-19 07:52PM  
06:55PM  
04:00PM  
Jul-31-19 01:48PM  
Jul-29-19 08:30PM  
Jul-19-19 09:30AM  
Jul-12-19 12:13PM  
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anicetti Vincent RChief Operating OfficerOct 19Option Exercise4.773,21715,35751,773Oct 21 04:04 PM
Anicetti Vincent RChief Operating OfficerOct 19Sale17.893,21757,55648,556Oct 21 04:04 PM
Viret Jean-FredericChief Financial OfficerOct 14Sale19.006,144116,73640,423Oct 16 04:19 PM
Anicetti Vincent RChief Operating OfficerSep 17Option Exercise7.605,00038,00153,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerSep 17Sale18.845,00094,21648,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerAug 17Option Exercise7.605,00038,00153,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerAug 17Sale19.375,00096,85148,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerJul 17Option Exercise11.0015,000165,00163,556Jul 21 05:04 PM
Anicetti Vincent RChief Operating OfficerJul 17Sale18.2515,000273,68748,556Jul 21 05:04 PM
Lanfear Dennis MPresident & CEOJul 01Option Exercise0.0129,994249193,258Jul 06 05:58 PM
Szela Mary TDirectorJun 22Option Exercise8.8454,997485,90054,997Jun 24 04:55 PM
Szela Mary TDirectorJun 22Sale17.5854,997966,7590Jun 24 04:55 PM
Anicetti Vincent RChief Operating OfficerJun 17Option Exercise2.502,5006,25151,056Jun 19 04:35 PM
Wahlstrom MatsDirectorJun 17Sale17.15200,0003,430,0200Jun 19 04:33 PM
Anicetti Vincent RChief Operating OfficerJun 17Sale17.222,50043,05048,556Jun 19 04:35 PM
Viret Jean-FredericChief Financial OfficerMay 20Sale17.661,27822,56946,567May 22 04:30 PM
Anicetti Vincent RChief Operating OfficerMay 18Option Exercise2.502,5006,25151,056May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerMay 18Sale17.173,09353,10748,556May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerApr 20Sale17.005,15087,55047,846Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Option Exercise2.505,00012,50357,996Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Sale15.575,00077,85052,996Apr 21 04:24 PM
Wahlstrom MatsDirectorMar 03Sale20.12118,0662,375,409200,000Mar 05 04:31 PM
Viret Jean-FredericChief Financial OfficerFeb 19Option Exercise10.053,15931,74850,000Feb 21 06:16 PM
Viret Jean-FredericChief Financial OfficerFeb 19Sale22.333,15970,55246,841Feb 21 06:16 PM
Anicetti Vincent RChief Operating OfficerFeb 18Option Exercise7.605,00038,00160,496Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerFeb 18Sale21.6410,000216,39052,996Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerJan 17Option Exercise7.605,00038,00165,496Jan 22 04:06 PM
Anicetti Vincent RChief Operating OfficerJan 17Sale19.5910,000195,93157,996Jan 22 04:06 PM
Viret Jean-FredericChief Financial OfficerJan 15Option Exercise10.056,31863,49653,159Jan 17 04:11 PM
Viret Jean-FredericChief Financial OfficerJan 15Sale19.856,318125,42446,841Jan 17 04:11 PM
HEALY JAMESDirectorJan 12Option Exercise12.3720,000247,40070,086Jan 13 04:45 PM
HEALY JAMESDirectorJan 09Option Exercise5.0249,994251,00050,086Jan 13 04:45 PM
Anicetti Vincent RChief Operating OfficerDec 16Option Exercise2.502,5006,25121,826Dec 18 04:28 PM
Anicetti Vincent RChief Operating OfficerDec 16Sale18.692,50046,72519,326Dec 18 04:28 PM
Lanfear Dennis MPresident & CEONov 21Sale18.5612,500231,960446,684Nov 25 04:03 PM
Viret Jean-FredericChief Financial OfficerNov 20Option Exercise10.053,15931,7486,462Nov 22 04:09 PM
Lanfear Dennis MPresident & CEONov 20Sale18.00825,00014,850,000459,184Nov 22 06:56 PM
Viret Jean-FredericChief Financial OfficerNov 20Sale19.593,15961,8723,303Nov 22 04:09 PM
Viret Jean-FredericChief Financial OfficerNov 18Sale18.883,11258,7573,303Nov 20 04:22 PM
Anicetti Vincent RChief Operating OfficerNov 14Option Exercise2.502,5006,25121,810Nov 18 04:10 PM
Anicetti Vincent RChief Operating OfficerNov 14Sale19.262,50048,15019,310Nov 18 04:10 PM
TWST Twist Bioscience Corporation daily Stock Chart
TWST [NASD]
Twist Bioscience Corporation
Index- P/E- EPS (ttm)-4.18 Insider Own3.00% Shs Outstand41.84M Perf Week-9.43%
Market Cap3.89B Forward P/E- EPS next Y-2.29 Insider Trans-32.90% Shs Float40.80M Perf Month29.30%
Income-146.80M PEG- EPS next Q-0.70 Inst Own94.30% Short Float10.66% Perf Quarter46.63%
Sales73.40M P/S52.98 EPS this Y-46.50% Inst Trans4.46% Short Ratio7.56 Perf Half Y159.26%
Book/sh8.34 P/B10.31 EPS next Y44.80% ROA-52.80% Target Price76.67 Perf Year268.50%
Cash/sh6.89 P/C12.47 EPS next 5Y- ROE-67.60% 52W Range18.52 - 100.30 Perf YTD309.38%
Dividend- P/FCF- EPS past 5Y- ROI-68.30% 52W High-14.29% Beta-
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin23.40% 52W Low364.20% ATR5.45
Employees414 Current Ratio11.00 Sales Q/Q55.90% Oper. Margin- RSI (14)53.96 Volatility6.60% 6.67%
OptionableYes Debt/Eq0.02 EPS Q/Q26.80% Profit Margin- Rel Volume1.01 Prev Close87.06
ShortableYes LT Debt/Eq0.01 EarningsAug 06 AMC Payout- Avg Volume574.76K Price85.97
Recom2.00 SMA200.41% SMA5015.95% SMA20086.58% Volume581,656 Change-1.25%
Oct-20-20Initiated SVB Leerink Mkt Perform $90
May-31-19Initiated Evercore ISI Outperform
Nov-26-18Initiated JP Morgan Neutral $27
Oct-20-20 09:56AM  
Oct-13-20 03:03PM  
08:00AM  
07:00AM  
Sep-18-20 08:00AM  
Sep-16-20 01:38PM  
Sep-03-20 08:00AM  
Sep-02-20 08:00AM  
Aug-20-20 08:00AM  
Aug-13-20 10:35AM  
Aug-06-20 07:10PM  
04:05PM  
Aug-04-20 08:00AM  
Jul-30-20 12:34PM  
08:00AM  
Jul-28-20 08:00AM  
Jul-23-20 08:00AM  
Jul-22-20 08:21AM  
08:00AM  
Jul-16-20 08:00AM  
Jul-15-20 02:20PM  
Jul-08-20 08:00AM  
Jul-01-20 08:12AM  
Jun-30-20 08:00AM  
Jun-28-20 05:23PM  
Jun-11-20 08:00AM  
Jun-09-20 08:30AM  
Jun-08-20 04:05PM  
Jun-03-20 10:16PM  
04:27PM  
Jun-01-20 08:00AM  
May-26-20 08:00AM  
May-17-20 04:15PM  
May-12-20 08:00AM  
May-08-20 05:30PM  
May-07-20 08:10PM  
04:05PM  
May-06-20 08:00AM  
Apr-30-20 08:00AM  
Apr-28-20 12:33PM  
Apr-20-20 08:30AM  
08:00AM  
Apr-13-20 10:55AM  
Mar-26-20 08:00AM  
Mar-25-20 08:00AM  
Mar-24-20 04:23PM  
Mar-16-20 08:00AM  
Mar-12-20 08:00AM  
Feb-26-20 08:05AM  
08:00AM  
Feb-25-20 08:00AM  
Feb-24-20 04:05PM  
08:00AM  
06:00AM  
Feb-19-20 07:51PM  
Feb-18-20 04:11PM  
Feb-12-20 08:00AM  
Feb-06-20 02:30PM  
07:47AM  
Jan-31-20 04:18PM  
Jan-23-20 11:26AM  
09:15AM  
08:00AM  
Jan-15-20 12:00PM  
08:00AM  
Jan-13-20 08:00AM  
Jan-06-20 08:00AM  
Dec-17-19 07:21PM  
Dec-12-19 07:38AM  
Dec-11-19 04:05PM  
08:00AM  
Nov-22-19 08:24AM  
Nov-20-19 08:01AM  
08:00AM  
Nov-13-19 08:00AM  
Nov-08-19 08:00AM  
Oct-30-19 08:00AM  
Oct-28-19 02:15PM  
Oct-25-19 08:00AM  
Oct-24-19 02:01PM  
Oct-16-19 08:00AM  
Oct-01-19 08:00AM  
Sep-24-19 08:00AM  
Aug-30-19 08:00AM  
Aug-28-19 08:15PM  
Aug-19-19 07:14PM  
Aug-02-19 07:43PM  
Aug-01-19 04:05PM  
Jul-29-19 08:00AM  
Jul-25-19 08:01AM  
08:00AM  
Jun-17-19 08:00AM  
May-28-19 08:00AM  
May-23-19 08:00AM  
08:00AM  
May-16-19 08:00AM  
May-14-19 08:41AM  
May-13-19 11:55AM  
May-08-19 08:03PM  
May-06-19 04:10PM  
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has collaboration agreements with Pandion Therapeutics, Inc. and Schrodinger Inc. It also has a partnership with Serimmune Inc. to identify and evaluate SARS-CoV-2 therapeutic antibody candidates. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weiss PatrickChief Operating OfficerOct 09Option Exercise8.713,55030,93560,118Oct 13 04:09 PM
Weiss PatrickChief Operating OfficerOct 09Sale86.633,550307,53756,699Oct 13 04:09 PM
Weiss PatrickChief Operating OfficerOct 08Option Exercise8.713,55030,93560,118Oct 13 04:09 PM
Weiss PatrickChief Operating OfficerOct 08Sale89.583,550318,00956,699Oct 13 04:09 PM
Weiss PatrickChief Operating OfficerSep 18Option Exercise8.713,55030,93560,118Sep 21 04:58 PM
Weiss PatrickChief Operating OfficerSep 18Sale65.213,550231,49656,699Sep 21 04:58 PM
Weiss PatrickChief Operating OfficerSep 17Option Exercise8.713,55030,93567,689Sep 21 04:58 PM
Weiss PatrickChief Operating OfficerSep 17Sale60.7511,121675,60156,699Sep 21 04:58 PM
Green PaulaVP of Human ResourcesSep 16Option Exercise6.9226,988186,82546,458Sep 18 05:08 PM
Green PaulaVP of Human ResourcesSep 16Sale63.3726,9881,710,10028,615Sep 18 05:08 PM
THORBURN JAMES MChief Financial OfficerSep 09Option Exercise26.6620,000533,20071,719Sep 11 04:13 PM
THORBURN JAMES MChief Financial OfficerSep 09Sale65.9620,0001,319,12451,719Sep 11 04:13 PM
THORBURN JAMES MChief Financial OfficerSep 08Option Exercise13.8770,000970,876111,130Sep 09 06:03 PM
THORBURN JAMES MChief Financial OfficerSep 08Sale63.0870,0004,415,79051,719Sep 09 06:03 PM
Leproust Emily M.President & CEOSep 08Sale60.353,482210,156607,698Sep 09 06:04 PM
THORBURN JAMES MChief Financial OfficerSep 04Option Exercise11.5930,000347,70081,719Sep 09 06:03 PM
Leproust Emily M.President & CEOSep 04Sale63.0896,5186,088,154611,180Sep 09 06:04 PM
THORBURN JAMES MChief Financial OfficerSep 04Sale63.5830,0001,907,30951,719Sep 09 06:03 PM
Finn Patrick JohnChief Commercial OfficerAug 31Option Exercise8.822,35820,79838,748Sep 02 04:41 PM
Finn Patrick JohnChief Commercial OfficerAug 27Sale67.222,358158,49536,390Aug 31 07:11 PM
Daniels MarkSee RemarksAug 17Option Exercise5.9520,994124,91474,712Aug 18 06:52 PM
Daniels MarkSee RemarksAug 17Sale68.0720,9941,429,09853,718Aug 18 06:52 PM
Daniels MarkSee RemarksAug 14Option Exercise5.959,00653,58662,724Aug 17 04:24 PM
Daniels MarkSee RemarksAug 14Sale66.179,006595,90253,718Aug 17 04:24 PM
Daniels MarkSee RemarksAug 13Option Exercise5.9514,50286,28768,220Aug 17 04:24 PM
Daniels MarkSee RemarksAug 13Sale64.5314,502935,83853,718Aug 17 04:24 PM
Leproust Emily M.President & CEOAug 07Sale69.9814,000979,786689,055Aug 11 04:26 PM
Finn Patrick JohnChief Commercial OfficerJul 31Option Exercise8.822,35820,79839,097Aug 04 04:46 PM
Finn Patrick JohnChief Commercial OfficerJul 31Option Exercise8.822,35820,79839,097Aug 04 04:42 PM
Finn Patrick JohnChief Commercial OfficerJul 23Sale59.112,358139,37536,739Jul 27 05:31 PM
Leproust Emily M.President & CEOJul 21Sale59.3315,000889,967703,055Jul 22 05:48 PM
Banyai WilliamSee RemarksJul 16Sale53.1211,000584,282493,592Jul 17 06:10 PM
Banyai WilliamSee RemarksJul 15Sale55.6111,000611,694504,592Jul 17 06:10 PM
Finn Patrick JohnChief Commercial OfficerJul 08Option Exercise26.6628,820768,34139,097Jul 10 06:45 AM
Banyai WilliamSee RemarksJul 08Sale53.1525,0001,328,793515,592Jul 10 04:15 PM
Leproust Emily M.President & CEOJul 08Sale50.3719,700992,289718,055Jul 10 06:44 AM
Leproust Emily M.President & CEOJul 07Sale49.0030014,700737,755Jul 10 06:44 AM
Finn Patrick JohnChief Commercial OfficerJul 07Sale47.1116,084757,65810,277Jul 10 06:45 AM
Finn Patrick JohnChief Commercial OfficerJul 06Sale46.6911,336529,27126,361Jul 08 05:52 PM
Finn Patrick JohnChief Commercial OfficerJul 02Sale46.681,40065,35437,697Jul 07 08:05 PM
Finn Patrick JohnChief Commercial OfficerJun 25Option Exercise8.828417,41839,097Jun 29 06:05 PM
Daniels MarkSee RemarksJun 16Option Exercise5.953,53621,03957,254Jun 17 05:18 PM
Banyai WilliamSee RemarksJun 16Sale38.7511,000426,204540,592Jun 17 05:18 PM
Daniels MarkSee RemarksJun 16Sale38.803,536137,18153,718Jun 17 05:18 PM
Green PaulaVP of Human ResourcesJun 15Option Exercise5.9516,833100,15639,448Jun 17 05:17 PM
Banyai WilliamSee RemarksJun 15Sale38.1511,000419,607551,592Jun 17 05:18 PM
Green PaulaVP of Human ResourcesJun 15Sale38.0016,833639,65422,615Jun 17 05:17 PM
Daniels MarkSee RemarksJun 10Sale40.001,96278,48053,718Jun 11 06:42 PM
Weiss PatrickChief Operating OfficerJun 08Sale37.2520,000744,94057,606Jun 10 04:44 PM
Leproust Emily M.President & CEOJun 01Sale39.1424,500958,888738,055Jun 03 05:03 PM
Banyai WilliamSee RemarksJun 01Sale40.0120,113804,641562,592Jun 03 05:04 PM
Finn Patrick JohnChief Commercial OfficerMay 29Option Exercise8.828417,41838,256Jun 01 06:27 PM
Finn Patrick JohnChief Commercial OfficerMay 28Sale37.092,11678,48537,415Jun 01 06:27 PM
Finn Patrick JohnChief Commercial OfficerMay 26Option Exercise38.464,207161,80139,531May 28 07:44 PM
Leproust Emily M.President & CEOMay 26Sale39.0710,593413,827762,555May 27 06:26 PM
Leproust Emily M.President & CEOMay 22Sale39.2714,513569,923773,148May 27 06:26 PM
Banyai WilliamSee RemarksMay 21Sale40.034,887195,629582,705May 22 09:07 PM
Leproust Emily M.President & CEOMay 21Sale39.5414,438570,852787,661May 22 09:07 PM
Leproust Emily M.President & CEOMay 20Sale39.7540,9561,627,811805,106May 22 09:07 PM
Banyai WilliamSee RemarksMay 20Sale39.6622,000872,617588,267May 22 09:07 PM
Finn Patrick JohnChief Commercial OfficerMay 20Sale39.694,207166,95735,999May 22 09:06 PM
Weiss PatrickChief Operating OfficerFeb 19Sale28.661,74249,92474,037Feb 20 04:28 PM
Banyai WilliamSee RemarksFeb 18Sale30.7111,000337,777611,033Feb 20 04:27 PM
Weiss PatrickChief Operating OfficerFeb 18Sale30.694,090125,53875,779Feb 20 04:28 PM
Weiss PatrickChief Operating OfficerFeb 06Option Exercise26.667,680204,74985,950Feb 10 08:10 PM
Weiss PatrickChief Operating OfficerFeb 06Sale28.167,680216,25379,869Feb 10 08:10 PM
Weiss PatrickChief Operating OfficerFeb 05Sale26.184,089107,03579,869Feb 06 09:01 PM
Weiss PatrickChief Operating OfficerFeb 04Sale26.214,090107,19383,958Feb 06 09:01 PM
Finn Patrick JohnChief Commercial OfficerJan 23Option Exercise8.8215,000132,30040,472Jan 24 04:34 PM
Finn Patrick JohnChief Commercial OfficerJan 22Sale22.5215,000337,83125,472Jan 24 04:34 PM
Weiss PatrickChief Operating OfficerJan 22Sale22.464,08991,84288,048Jan 23 04:59 PM
Weiss PatrickChief Operating OfficerJan 21Sale22.294,08991,14192,137Jan 23 04:59 PM
BBI Brickell Biotech, Inc. daily Stock Chart
BBI [NASD]
Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own2.30% Shs Outstand27.79M Perf Week-44.31%
Market Cap20.00M Forward P/E- EPS next Y-0.81 Insider Trans6.30% Shs Float25.05M Perf Month-33.47%
Income-24.90M PEG- EPS next Q-0.19 Inst Own21.10% Short Float1.03% Perf Quarter-45.32%
Sales3.50M P/S5.71 EPS this Y13.60% Inst Trans1.01% Short Ratio0.13 Perf Half Y-56.39%
Book/sh1.68 P/B0.31 EPS next Y- ROA-110.90% Target Price- Perf Year-82.04%
Cash/sh0.56 P/C0.93 EPS next 5Y- ROE-193.40% 52W Range0.71 - 4.00 Perf YTD-65.41%
Dividend- P/FCF- EPS past 5Y19.10% ROI-291.40% 52W High-87.03% Beta-0.19
Dividend %- Quick Ratio3.80 Sales past 5Y-12.30% Gross Margin- 52W Low-26.93% ATR0.08
Employees15 Current Ratio3.80 Sales Q/Q-76.90% Oper. Margin- RSI (14)24.89 Volatility11.85% 8.11%
OptionableNo Debt/Eq0.02 EPS Q/Q93.30% Profit Margin- Rel Volume7.79 Prev Close0.72
ShortableNo LT Debt/Eq0.01 EarningsAug 12 AMC Payout- Avg Volume1.98M Price0.52
Recom1.50 SMA20-41.79% SMA50-39.16% SMA200-57.71% Volume15,432,812 Change-27.94%
Aug-28-20Initiated Lake Street Buy $6
Aug-25-20Initiated Oppenheimer Outperform $5
Oct-22-20 08:00PM  
Sep-29-20 10:30AM  
Sep-25-20 07:00AM  
Sep-10-20 04:05PM  
Sep-08-20 07:30AM  
Aug-31-20 04:05PM  
Aug-12-20 04:01PM  
Aug-03-20 04:05PM  
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
02:30PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
06:30AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. Brickell Biotech, Inc. has collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19 in the United States. The company was founded in 2009 and is based in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McAvoy David R.General Counsel and CCOSep 18Buy0.846,0005,0396,000Sep 21 04:19 PM
McAvoy David R.General Counsel and CCOSep 18Buy0.8316,52613,71375,883Sep 21 04:19 PM
VERU DENNISON TDirectorSep 16Buy0.8014,64511,75850,810Sep 17 05:07 PM
VERU DENNISON TDirectorSep 15Buy0.8115,35512,41636,165Sep 17 05:07 PM
ADPT Adaptive Biotechnologies Corporation daily Stock Chart
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.79 Insider Own1.30% Shs Outstand127.38M Perf Week-4.24%
Market Cap6.37B Forward P/E- EPS next Y-1.09 Insider Trans-70.64% Shs Float82.04M Perf Month8.03%
Income-99.50M PEG- EPS next Q-0.28 Inst Own75.90% Short Float6.36% Perf Quarter30.78%
Sales92.20M P/S69.12 EPS this Y-42.00% Inst Trans1.92% Short Ratio5.77 Perf Half Y54.59%
Book/sh4.16 P/B11.90 EPS next Y-1.90% ROA-11.20% Target Price53.17 Perf Year90.38%
Cash/sh4.43 P/C11.17 EPS next 5Y3.90% ROE-17.80% 52W Range15.19 - 54.20 Perf YTD65.44%
Dividend- P/FCF- EPS past 5Y- ROI-12.90% 52W High-8.67% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin76.30% 52W Low225.87% ATR2.22
Employees453 Current Ratio6.40 Sales Q/Q-5.00% Oper. Margin- RSI (14)54.02 Volatility5.59% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-90.50% Profit Margin- Rel Volume0.72 Prev Close46.93
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume904.34K Price49.50
Recom1.60 SMA20-0.51% SMA509.58% SMA20034.34% Volume655,389 Change5.48%
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Oct-13-20 04:05PM  
Sep-28-20 10:52AM  
Sep-01-20 04:03PM  
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Feb-19-20 04:05PM  
Feb-12-20 04:05PM  
Feb-10-20 08:44AM  
Feb-03-20 11:27AM  
Jan-31-20 11:52AM  
Jan-29-20 09:50AM  
Jan-23-20 08:53PM  
Jan-22-20 08:25AM  
Jan-21-20 04:39PM  
04:02PM  
Jan-13-20 07:30AM  
Jan-08-20 07:30AM  
Dec-30-19 04:05PM  
10:04AM  
Dec-26-19 02:47PM  
Dec-20-19 04:17PM  
Dec-16-19 09:24PM  
Dec-13-19 04:52AM  
Dec-09-19 08:44AM  
08:00AM  
Dec-04-19 04:30PM  
Dec-03-19 04:34PM  
Nov-22-19 03:01AM  
Nov-19-19 12:26PM  
Nov-12-19 04:05PM  
Nov-11-19 09:28AM  
Oct-29-19 04:05PM  
Oct-14-19 06:43PM  
Oct-09-19 08:37AM  
Sep-26-19 07:13AM  
Sep-25-19 08:44AM  
Sep-24-19 08:00AM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENZENO SHARONChief Business Development OffOct 19Option Exercise6.274172,615417Oct 20 07:00 PM
BENZENO SHARONChief Business Development OffOct 19Sale51.2541721,3710Oct 20 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 16Option Exercise6.3211,10070,15211,779Oct 20 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 16Sale51.7911,100574,869679Oct 20 07:00 PM
HERSHBERG ROBERTDirectorOct 15Option Exercise0.452,0009002,000Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 15Option Exercise7.802,00015,6002,000Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 15Option Exercise6.3211,10070,15211,779Oct 16 05:00 PM
HERSHBERG ROBERTDirectorOct 15Sale51.512,000103,0200Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 15Sale51.512,000103,0200Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 15Sale51.5511,100572,205679Oct 16 05:00 PM
Pellini Michael JDirectorOct 14Option Exercise6.5550,000327,50050,000Oct 16 05:00 PM
GRIFFIN MICHELLE RENEEDirectorOct 14Option Exercise7.8012,00093,60012,000Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 14Option Exercise6.3211,10070,15211,779Oct 16 05:00 PM
Pellini Michael JDirectorOct 14Sale52.3550,0002,617,5500Oct 16 05:00 PM
GRIFFIN MICHELLE RENEEDirectorOct 14Sale52.8412,000634,0970Oct 16 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 14Sale52.1711,100579,133679Oct 16 05:00 PM
LO FRANCISChief People OfficerOct 12Option Exercise7.8025,000195,00025,000Oct 14 09:00 PM
LO FRANCISChief People OfficerOct 12Sale52.8025,0001,320,0000Oct 14 09:00 PM
Cohen Chad MChief Financial OfficerOct 08Option Exercise6.3230,000189,60031,000Oct 08 07:24 PM
ROBINS CHAD MCEO and ChairmanOct 08Option Exercise0.3324,2608,0061,802,440Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 08Sale50.6124,2601,227,7201,778,180Oct 08 07:26 PM
Cohen Chad MChief Financial OfficerOct 08Sale50.6530,0001,519,4291,000Oct 08 07:24 PM
ROBINS CHAD MCEO and ChairmanOct 07Option Exercise0.3350,00016,5001,828,180Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 07Sale50.1850,0002,509,0401,778,180Oct 08 07:26 PM
ROBINS CHAD MCEO and ChairmanOct 06Option Exercise0.3318,2806,0321,796,460Oct 08 07:26 PM
BALDO LANCEChief Medical OfficerOct 06Option Exercise7.806,25048,7506,250Oct 07 07:00 PM
ROBINS CHAD MCEO and ChairmanOct 06Sale49.3618,280902,3431,778,180Oct 08 07:26 PM
BALDO LANCEChief Medical OfficerOct 06Sale49.206,250307,5180Oct 07 07:00 PM
BENZENO SHARONChief Business Development OffOct 01Option Exercise6.726,77145,4756,771Oct 02 07:00 PM
DOBMEIER ERICDirectorOct 01Option Exercise6.3210,00063,20010,000Oct 02 07:00 PM
RUBINSTEIN JULIEPresidentOct 01Option Exercise0.8414,72512,36914,725Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanOct 01Option Exercise0.336001981,778,780Oct 01 08:00 PM
BENZENO SHARONChief Business Development OffOct 01Sale48.576,771328,8370Oct 02 07:00 PM
DOBMEIER ERICDirectorOct 01Sale48.5310,000485,2740Oct 02 07:00 PM
RUBINSTEIN JULIEPresidentOct 01Sale49.0014,725721,5250Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanOct 01Sale50.0560030,0301,778,180Oct 01 08:00 PM
RUBINSTEIN JULIEPresidentSep 29Option Exercise0.8480,00067,20080,000Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 29Option Exercise0.331,9006271,780,080Oct 01 08:00 PM
BALDO LANCEChief Medical OfficerSep 29Option Exercise7.8025,000195,00025,000Oct 01 08:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQSep 29Option Exercise1.9810,00019,80010,000Oct 01 08:00 PM
RUBINSTEIN JULIEPresidentSep 29Sale49.0080,0003,920,0000Oct 01 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 29Sale50.181,90095,3421,778,180Oct 01 08:00 PM
BALDO LANCEChief Medical OfficerSep 29Sale50.0025,0001,250,0000Oct 01 08:00 PM
BOBULSKY SUSANSVP, Diagnostics, clonoSEQSep 29Sale50.0010,000500,0000Oct 01 08:00 PM
Taylor Stacy LSVP and General CounselSep 24Option Exercise7.032,88020,2504,180Sep 28 08:00 PM
ROBINS HARLAN SChief Scientific OfficerSep 24Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
Taylor Stacy LSVP and General CounselSep 24Sale47.782,880137,5961,300Sep 28 08:00 PM
ROBINS HARLAN SChief Scientific OfficerSep 24Sale47.1111,100522,879679Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 23Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 23Sale48.1611,100534,576679Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 22Option Exercise6.3211,10070,15211,779Sep 24 08:24 PM
ROBINS HARLAN SChief Scientific OfficerSep 22Sale47.5711,100527,975679Sep 24 08:24 PM
BENZENO SHARONChief Business Development OffSep 21Option Exercise6.274172,615417Sep 23 08:00 PM
BENZENO SHARONChief Business Development OffSep 21Sale45.5141718,9780Sep 23 08:00 PM
ROBINS CHAD MCEO and ChairmanSep 18Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 18Sale45.7216,680762,5631,778,180Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 17Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 17Sale45.1416,680752,9091,778,180Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 16Option Exercise0.3316,6805,5041,794,860Sep 18 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 16Sale46.4416,680774,6051,738,680Sep 18 09:00 PM
HERSHBERG ROBERTDirectorSep 15Option Exercise0.452,0009002,000Sep 16 09:00 PM
LO FRANCISChief People OfficerSep 15Option Exercise7.802,00015,6002,000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 15Option Exercise6.3225,000158,00025,000Sep 16 09:00 PM
HERSHBERG ROBERTDirectorSep 15Sale42.582,00085,1600Sep 16 09:00 PM
LO FRANCISChief People OfficerSep 15Sale42.582,00085,1600Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 15Sale44.0025,0001,100,0000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 14Option Exercise6.5525,000163,75025,000Sep 16 09:00 PM
SANG CHARLESSVP, External AffairsSep 14Sale42.5025,0001,062,5000Sep 16 09:00 PM
Cohen Chad MChief Financial OfficerSep 11Option Exercise6.328,58854,2769,588Sep 11 09:00 PM
BALDO LANCEChief Medical OfficerSep 11Option Exercise7.804,14932,3624,149Sep 11 09:00 PM
BALDO LANCEChief Medical OfficerSep 11Sale40.004,149165,9600Sep 11 09:00 PM
Cohen Chad MChief Financial OfficerSep 11Sale40.008,588343,5201,000Sep 11 09:00 PM
Cohen Chad MChief Financial OfficerSep 10Option Exercise6.321,4128,9242,412Sep 11 09:00 PM
BALDO LANCEChief Medical OfficerSep 10Option Exercise7.801814018Sep 11 09:00 PM
Cohen Chad MChief Financial OfficerSep 10Sale40.001,41256,4801,000Sep 11 09:00 PM
BALDO LANCEChief Medical OfficerSep 10Sale40.00187200Sep 11 09:00 PM
Cohen Chad MChief Financial OfficerSep 08Option Exercise6.3220,000126,40021,000Sep 09 07:00 PM
BALDO LANCEChief Medical OfficerSep 08Option Exercise7.802,08316,2472,083Sep 09 07:00 PM
Cohen Chad MChief Financial OfficerSep 08Sale36.1720,000723,4001,000Sep 09 07:00 PM
BALDO LANCEChief Medical OfficerSep 08Sale36.172,08375,3420Sep 09 07:00 PM
BENZENO SHARONChief Business Development OffSep 01Option Exercise6.726,77145,4756,771Sep 02 08:00 PM
BENZENO SHARONChief Business Development OffSep 01Sale41.306,771279,6480Sep 02 08:00 PM
Taylor Stacy LSVP and General CounselAug 24Option Exercise7.032,88020,2504,180Aug 24 08:00 PM
Taylor Stacy LSVP and General CounselAug 24Sale42.582,880122,6351,300Aug 24 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 21Option Exercise6.3211,10070,15211,779Aug 24 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 21Sale43.1211,100478,658679Aug 24 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 20Option Exercise6.3211,10070,15211,779Aug 24 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 20Sale42.9311,100476,527679Aug 24 08:00 PM
BENZENO SHARONChief Business Development OffAug 19Option Exercise6.274162,608416Aug 19 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 19Option Exercise6.3211,10070,15211,779Aug 24 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 19Sale42.4811,100471,513679Aug 24 08:00 PM
BENZENO SHARONChief Business Development OffAug 19Sale41.5741617,2930Aug 19 08:00 PM
LO FRANCISChief People OfficerAug 17Option Exercise7.802,00015,6002,000Aug 19 08:00 PM
HERSHBERG ROBERTDirectorAug 17Option Exercise0.452,0009002,000Aug 19 08:00 PM
Cohen Chad MChief Financial OfficerAug 17Option Exercise6.3210,00063,20011,000Aug 19 08:00 PM
LO FRANCISChief People OfficerAug 17Sale39.362,00078,7250Aug 19 08:00 PM
HERSHBERG ROBERTDirectorAug 17Sale39.392,00078,7710Aug 19 08:00 PM
Cohen Chad MChief Financial OfficerAug 17Sale40.0010,000400,0001,000Aug 19 08:00 PM
ROBINS CHAD MCEO and ChairmanAug 12Option Exercise0.3316,6805,5041,794,860Aug 12 09:00 PM
ROBINS CHAD MCEO and ChairmanAug 12Sale37.427,675287,1821,787,185Aug 12 09:00 PM
RVMD Revolution Medicines, Inc. daily Stock Chart
RVMD [NASD]
Revolution Medicines, Inc.
Index- P/E- EPS (ttm)-21.25 Insider Own0.40% Shs Outstand58.75M Perf Week-11.26%
Market Cap2.60B Forward P/E- EPS next Y-1.67 Insider Trans-65.83% Shs Float43.70M Perf Month28.53%
Income- PEG- EPS next Q-0.39 Inst Own73.70% Short Float7.70% Perf Quarter57.63%
Sales46.17M P/S56.33 EPS this Y-13.70% Inst Trans2.80% Short Ratio7.86 Perf Half Y37.13%
Book/sh6.14 P/B6.57 EPS next Y7.70% ROA- Target Price42.25 Perf Year-
Cash/sh5.05 P/C7.99 EPS next 5Y- ROE- 52W Range17.34 - 47.14 Perf YTD39.69%
Dividend- P/FCF- EPS past 5Y- ROI32.60% 52W High-14.36% Beta-
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low132.75% ATR2.63
Employees106 Current Ratio7.80 Sales Q/Q-24.20% Oper. Margin- RSI (14)56.61 Volatility8.91% 6.29%
OptionableNo Debt/Eq0.00 EPS Q/Q-113.40% Profit Margin- Rel Volume0.64 Prev Close39.45
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume428.07K Price40.37
Recom1.80 SMA202.20% SMA5023.06% SMA20033.52% Volume275,574 Change2.33%
May-21-20Initiated H.C. Wainwright Buy $55
Mar-09-20Initiated JP Morgan Neutral $32
Mar-09-20Initiated Guggenheim Buy $50
Mar-09-20Initiated Cowen Outperform
Oct-24-20 09:45AM  
06:00AM  
Oct-12-20 07:30AM  
Sep-22-20 08:52AM  
Sep-18-20 04:16PM  
Sep-16-20 09:00AM  
Sep-09-20 07:30AM  
Sep-08-20 07:30AM  
Aug-28-20 11:12AM  
Aug-10-20 07:30AM  
Jul-13-20 04:01PM  
08:53AM  
Jul-06-20 04:01PM  
Jun-30-20 04:05PM  
Jun-22-20 04:01PM  
07:30AM  
Jun-18-20 07:30AM  
Jun-09-20 07:30AM  
May-22-20 10:29PM  
May-19-20 07:30AM  
May-14-20 04:05PM  
Apr-29-20 08:05AM  
Mar-18-20 07:30AM  
Mar-09-20 07:30AM  
Feb-18-20 04:01PM  
Feb-14-20 01:24PM  
Feb-13-20 11:20AM  
Feb-12-20 07:56PM  
07:39PM  
Feb-11-20 07:12AM  
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDERSON ELIZABETH MDirectorOct 15Sale45.004,780215,10026,990Oct 15 07:15 PM
Anders JackSee RemarksOct 13Option Exercise2.6810,00026,80010,000Oct 15 07:14 PM
ANDERSON ELIZABETH MDirectorOct 13Sale45.002209,90031,770Oct 15 07:15 PM
Anders JackSee RemarksOct 13Sale44.0010,000440,0000Oct 15 07:14 PM
Anders JackSee RemarksOct 06Option Exercise2.6810,00026,80010,000Oct 08 05:07 PM
Miller Vincent A.DirectorOct 06Sale39.006,250243,75020,133Oct 08 05:07 PM
ANDERSON ELIZABETH MDirectorOct 06Sale40.005,000200,00031,990Oct 08 05:06 PM
Anders JackSee RemarksOct 06Sale40.0010,000400,0000Oct 08 05:07 PM
Weber BarbaraDirectorOct 05Option Exercise1.127,1968,0609,004Oct 05 08:17 PM
Weber BarbaraDirectorOct 05Sale36.177,196260,3131,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 02Option Exercise1.128049002,612Oct 05 08:17 PM
Horn Margaret ASee RemarksOct 02Sale35.4012,495442,32153,302Oct 02 07:01 PM
Weber BarbaraDirectorOct 02Sale36.0280428,9601,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 01Option Exercise1.122,0002,2403,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 01Sale34.762,00069,5211,808Oct 05 08:17 PM
Horn Margaret ASee RemarksOct 01Sale35.0157,5052,013,17065,797Oct 02 07:01 PM
Kelsey Stephen MichaelSee RemarksSep 30Option Exercise4.7317,24881,583253,577Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 30Option Exercise4.7342,578201,28642,578Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 30Sale34.121,31244,76271,879Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 30Sale34.4042,5781,464,8540Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 30Sale34.3317,248592,060236,329Sep 30 08:31 PM
Kelsey Stephen MichaelSee RemarksSep 29Option Exercise4.7313,26862,758249,597Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 29Option Exercise4.5130,523137,68830,523Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 29Sale34.0821,088718,65273,191Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 29Sale34.1430,5231,041,9180Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 29Sale34.1413,268452,914236,329Sep 30 08:31 PM
Miller Vincent A.DirectorSep 29Sale34.0745015,33226,383Sep 30 08:33 PM
Kelsey Stephen MichaelSee RemarksSep 28Option Exercise4.739,38444,386245,713Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 28Option Exercise4.0910,13241,44010,132Sep 30 08:32 PM
Miller Vincent A.DirectorSep 28Sale34.115,300180,77226,833Sep 30 08:33 PM
Kelsey Stephen MichaelSee RemarksSep 28Sale34.089,384319,831236,329Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 28Sale34.087,500255,60594,279Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 28Sale34.1110,132345,5670Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 23Option Exercise4.73100473236,429Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 23Option Exercise4.09100409100Sep 23 08:36 PM
Miller Vincent A.DirectorSep 23Sale34.0250017,01032,133Sep 25 04:29 PM
GOLDSMITH MARK ASee RemarksSep 23Sale34.021003,402101,779Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 23Sale34.011003,4010Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 23Sale34.021003,402236,329Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 22Option Exercise4.0910,09741,29710,097Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 22Sale33.00983,234236,329Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 22Sale33.0054117,853101,879Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 22Sale33.1510,097334,7130Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 21Option Exercise4.0929,903122,30329,903Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 21Sale33.0014,902491,805236,427Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 21Sale33.0011,459378,173102,420Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 21Sale33.0029,903986,8500Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 18Option Exercise3.577,34226,2097,342Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 18Sale31.0571222,106113,879Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 18Sale31.677,342232,5210Sep 18 08:01 PM
Kelsey Stephen MichaelSee RemarksSep 18Sale31.0363719,767251,329Sep 18 08:00 PM
GOLDSMITH MARK ASee RemarksSep 17Option Exercise1.1227,36330,64727,363Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 17Sale31.0311,288350,311114,591Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 17Sale30.8227,363843,2210Sep 18 08:01 PM
Kelsey Stephen MichaelSee RemarksSep 17Sale31.0311,363352,556251,966Sep 18 08:00 PM
GOLDSMITH MARK ASee RemarksSep 16Option Exercise1.128,8139,8718,813Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 16Sale29.048,813255,9560Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 10Option Exercise1.122,5442,8492,544Sep 11 06:35 PM
Kelsey Stephen MichaelSee RemarksSep 10Option Exercise4.731,0024,739265,871Sep 10 09:30 PM
Kelsey Stephen MichaelSee RemarksSep 10Sale29.062,54273,880263,329Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 10Sale29.004,399127,571125,879Sep 11 06:35 PM
GOLDSMITH MARK ASee RemarksSep 10Sale29.072,54473,9480Sep 11 06:35 PM
GOLDSMITH MARK ASee RemarksSep 09Sale29.001002,900130,251Sep 11 06:35 PM
Kelsey Stephen MichaelSee RemarksSep 09Sale29.041002,904264,869Sep 10 09:30 PM
Kelsey Stephen MichaelSee RemarksSep 08Option Exercise4.736002,838266,369Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 08Option Exercise1.129001,008900Sep 10 09:31 PM
GOLDSMITH MARK ASee RemarksSep 08Sale29.0590026,1450Sep 10 09:31 PM
Kelsey Stephen MichaelSee RemarksSep 08Sale29.061,40040,683264,969Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 08Sale29.0590026,141130,351Sep 10 09:31 PM
Kelsey Stephen MichaelSee RemarksSep 03Option Exercise4.737003,311267,169Sep 03 07:55 PM
GOLDSMITH MARK ASee RemarksSep 03Option Exercise1.12500560500Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 03Sale29.0770020,352131,251Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 03Sale29.0750014,5330Sep 04 07:05 PM
Kelsey Stephen MichaelSee RemarksSep 03Sale29.071,40040,699265,769Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 02Option Exercise4.73100473267,295Sep 03 07:55 PM
GOLDSMITH MARK ASee RemarksSep 02Option Exercise1.121,1001,2321,100Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 02Sale29.0280023,213131,951Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 02Sale29.051,10031,9600Sep 04 07:05 PM
Kelsey Stephen MichaelSee RemarksSep 02Sale29.0282623,973266,469Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 01Option Exercise4.6810,00046,841277,195Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 01Sale27.6710,000276,722267,195Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksAug 28Option Exercise4.09118483267,313Aug 31 07:08 PM
Kelsey Stephen MichaelSee RemarksAug 28Sale29.001183,422267,195Aug 31 07:08 PM
GOLDSMITH MARK ASee RemarksAug 27Option Exercise1.121,4381,6111,438Aug 31 07:09 PM
Kelsey Stephen MichaelSee RemarksAug 27Option Exercise4.098003,272268,809Aug 31 07:08 PM
GOLDSMITH MARK ASee RemarksAug 27Sale29.011,10131,939132,751Aug 31 07:09 PM
GOLDSMITH MARK ASee RemarksAug 27Sale29.011,43841,7130Aug 31 07:09 PM
Kelsey Stephen MichaelSee RemarksAug 27Sale29.011,61446,825267,195Aug 31 07:08 PM
Weber BarbaraDirectorAug 13Option Exercise1.123333732,141Aug 14 06:30 PM
Kelsey Stephen MichaelSee RemarksAug 13Option Exercise4.094,90020,041271,809Aug 14 06:31 PM
GOLDSMITH MARK ASee RemarksAug 13Option Exercise1.129,70010,8645,232Aug 14 06:32 PM
Kelsey Stephen MichaelSee RemarksAug 13Sale27.554,900134,995268,009Aug 14 06:31 PM
Weber BarbaraDirectorAug 13Sale28.003339,3241,808Aug 14 06:30 PM
GOLDSMITH MARK ASee RemarksAug 13Sale27.573,900107,522133,852Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 13Sale27.929,700270,7860Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 12Option Exercise1.1216,96719,00314,584Aug 14 06:32 PM
Weber BarbaraDirectorAug 12Option Exercise1.121,6671,8673,475Aug 14 06:30 PM
Kelsey Stephen MichaelSee RemarksAug 12Option Exercise4.0910,10041,309277,107Aug 14 06:31 PM
GOLDSMITH MARK ASee RemarksAug 12Sale25.916,100158,054137,752Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 12Sale25.9216,967439,7600Aug 14 06:32 PM
VIR Vir Biotechnology, Inc. daily Stock Chart
VIR [NASD]
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-6.17 Insider Own0.40% Shs Outstand114.98M Perf Week-11.99%
Market Cap4.74B Forward P/E- EPS next Y-2.30 Insider Trans-52.01% Shs Float109.06M Perf Month7.53%
Income-220.50M PEG- EPS next Q-0.60 Inst Own75.60% Short Float6.63% Perf Quarter-27.29%
Sales75.10M P/S63.05 EPS this Y-443.30% Inst Trans11.27% Short Ratio6.59 Perf Half Y5.02%
Book/sh4.90 P/B7.08 EPS next Y-2.20% ROA-42.30% Target Price55.00 Perf Year142.73%
Cash/sh4.05 P/C8.57 EPS next 5Y9.00% ROE-81.10% 52W Range11.65 - 75.00 Perf YTD176.02%
Dividend- P/FCF- EPS past 5Y- ROI-41.90% 52W High-53.72% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low197.93% ATR2.84
Employees253 Current Ratio10.50 Sales Q/Q3172.50% Oper. Margin- RSI (14)41.75 Volatility7.93% 7.49%
OptionableYes Debt/Eq0.00 EPS Q/Q52.60% Profit Margin- Rel Volume1.29 Prev Close37.27
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume1.10M Price34.71
Recom2.40 SMA20-9.80% SMA50-9.71% SMA200-2.24% Volume1,420,086 Change-6.87%
Oct-05-20Initiated BofA Securities Buy $55
Sep-14-20Upgrade Goldman Neutral → Buy $48 → $54
Sep-11-20Upgrade JP Morgan Underweight → Neutral $29
Aug-20-20Initiated Needham Buy $62
Mar-19-20Downgrade JP Morgan Neutral → Underweight $26
Mar-13-20Downgrade Goldman Buy → Neutral
Feb-27-20Downgrade Robert W. Baird Neutral → Underperform $17
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Oct-21-20 08:00AM  
Oct-13-20 04:01PM  
11:26AM  
Oct-12-20 09:31AM  
Oct-09-20 08:00AM  
Oct-07-20 01:44PM  
01:01PM  
08:47AM  
07:24AM  
Oct-06-20 04:25PM  
11:28AM  
10:46AM  
10:03AM  
09:49AM  
08:18AM  
Sep-29-20 06:08PM  
Sep-26-20 06:16AM  
Sep-24-20 08:00AM  
Sep-23-20 12:41PM  
Sep-22-20 10:01AM  
09:43AM  
Sep-15-20 06:30AM  
Sep-09-20 04:10PM  
Sep-08-20 04:01PM  
Sep-02-20 07:25AM  
Sep-01-20 04:01PM  
09:39AM  
09:09AM  
Aug-31-20 03:39PM  
03:17PM  
12:45PM  
08:50AM  
08:00AM  
Aug-20-20 09:51AM  
08:00AM  
Aug-11-20 04:01PM  
06:40AM  
Jul-28-20 04:01PM  
Jul-10-20 04:02PM  
04:01PM  
Jul-07-20 10:25PM  
05:58PM  
Jul-06-20 07:00AM  
Jun-08-20 02:06PM  
Jun-05-20 01:22PM  
Jun-04-20 03:57PM  
Jun-02-20 08:00AM  
Jun-01-20 12:23PM  
11:00AM  
May-29-20 08:00AM  
May-27-20 08:00AM  
May-23-20 08:13AM  
May-19-20 09:31AM  
May-18-20 05:28PM  
05:00PM  
02:47PM  
05:05AM  
May-15-20 03:09PM  
01:03PM  
May-12-20 04:01PM  
May-08-20 04:01PM  
May-07-20 04:01PM  
May-05-20 03:26PM  
03:11PM  
May-04-20 10:23AM  
08:24AM  
07:30AM  
Apr-28-20 08:00AM  
Apr-16-20 08:09AM  
Apr-15-20 04:01PM  
Apr-08-20 10:05AM  
07:00AM  
Apr-07-20 11:00AM  
Apr-06-20 04:03PM  
09:56AM  
08:12AM  
08:01AM  
Mar-30-20 07:00AM  
Mar-26-20 04:01PM  
10:52AM  
10:09AM  
08:23AM  
Mar-25-20 08:00AM  
Mar-18-20 05:49PM  
Mar-17-20 02:26PM  
Mar-16-20 03:41PM  
Mar-13-20 12:40PM  
11:01AM  
Mar-12-20 10:36AM  
10:07AM  
09:01AM  
08:00AM  
Mar-11-20 08:00AM  
Mar-10-20 08:25PM  
Mar-06-20 07:43AM  
Mar-05-20 09:19AM  
08:22AM  
Mar-04-20 03:38PM  
08:40AM  
07:37AM  
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pang PhillipChief Medical OfficerOct 21Option Exercise2.2112,50027,66742,277Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale35.4912,500443,60829,777Oct 22 06:15 PM
Virgin HerbertEVP, Research & CSOOct 13Option Exercise1.535,5608,50729,260Oct 14 06:33 PM
Virgin HerbertEVP, Research & CSOOct 13Sale43.035,560239,23623,700Oct 14 06:33 PM
Pang PhillipChief Medical OfficerOct 07Option Exercise1.5412,50019,22942,277Oct 08 05:00 PM
Pang PhillipChief Medical OfficerOct 07Sale41.7412,500521,79529,777Oct 08 05:00 PM
Parrish JayChief Business OfficerOct 01Option Exercise1.526,94510,522229,167Oct 02 05:19 PM
Parrish JayChief Business OfficerOct 01Sale34.756,945241,342222,222Oct 02 05:19 PM
Virgin HerbertEVP, Research & CSOSep 29Option Exercise1.533,5105,37027,210Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 29Sale38.003,510133,38023,700Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 24Option Exercise1.533,7005,66123,700Sep 28 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Option Exercise1.533,8055,82223,805Sep 23 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Sale31.713,805120,63820,000Sep 23 05:00 PM
Pang PhillipChief Medical OfficerSep 16Option Exercise2.2412,50028,00142,277Sep 18 05:00 PM
Pang PhillipChief Medical OfficerSep 16Sale31.9012,500398,69429,777Sep 18 05:00 PM
Virgin HerbertEVP, Research & CSOSep 08Option Exercise1.533,8055,82223,805Sep 10 04:30 PM
Virgin HerbertEVP, Research & CSOSep 08Sale29.993,805114,09820,000Sep 10 04:30 PM
Pang PhillipChief Medical OfficerSep 02Option Exercise1.5812,50019,68842,277Sep 03 04:23 PM
Pang PhillipChief Medical OfficerSep 02Sale32.8912,500411,15929,777Sep 03 04:23 PM
Parrish JayChief Business OfficerSep 01Option Exercise1.586,94310,935229,165Sep 03 04:22 PM
Parrish JayChief Business OfficerSep 01Sale39.156,943271,796222,222Sep 03 04:22 PM
Virgin HerbertEVP, Research & CSOAug 25Option Exercise1.5325,56039,10725,560Sep 10 04:29 PM
Virgin HerbertEVP, Research & CSOAug 25Sale42.925,560238,63220,000Sep 10 04:29 PM
Pang PhillipChief Medical OfficerAug 19Option Exercise1.5126,50039,99242,277Aug 21 04:39 PM
Pang PhillipChief Medical OfficerAug 19Sale50.9512,500636,85529,777Aug 21 04:39 PM
Virgin HerbertEVP, Research & CSOAug 11Option Exercise1.537,90012,0877,900Aug 12 04:30 PM
Virgin HerbertEVP, Research & CSOAug 11Sale51.087,900403,5630Aug 12 04:30 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:40 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:40 PM
Parrish JayChief Business OfficerAug 03Option Exercise1.5011,11016,665233,332Aug 04 05:14 PM
Parrish JayChief Business OfficerAug 03Sale47.6511,110529,404222,222Aug 04 05:14 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:28 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:03 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:28 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:03 PM
Pang PhillipChief Medical OfficerJul 15Option Exercise2.2412,50028,01828,277Jul 16 05:00 PM
Pang PhillipChief Medical OfficerJul 15Sale49.5312,500619,11815,777Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Option Exercise1.537,90012,0877,900Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Sale48.857,900385,8760Jul 16 05:00 PM
Horn HowardCFOJul 13Sale50.0630,0001,501,731177,777Jul 15 04:50 PM
Horn HowardCFOJul 02Sale40.0010,000400,000207,777Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Option Exercise1.5475,000115,792297,222Jul 02 06:43 PM
Pang PhillipChief Medical OfficerJul 01Option Exercise4.3712,50054,68728,277Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Sale37.9575,0002,846,310222,222Jul 02 06:43 PM
Horn HowardCFOJul 01Sale37.8410,000378,399217,777Jul 02 06:42 PM
Pang PhillipChief Medical OfficerJul 01Sale37.7812,500472,25215,777Jul 02 06:42 PM
Horn HowardCFOJun 25Sale50.0030,0001,500,000227,777Jun 26 05:00 PM
Virgin HerbertEVP, Research & CSOJun 24Option Exercise1.539,36014,3219,360Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 24Sale48.009,360449,2800Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Option Exercise1.535,5608,5075,560Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Sale38.995,560216,7780Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 19Option Exercise1.533,5105,3703,510Jun 23 05:00 PM
Horn HowardCFOJun 19Sale40.0010,000400,000257,777Jun 23 05:00 PM
Virgin HerbertEVP, Research & CSOJun 19Sale38.003,510133,3840Jun 23 05:00 PM
Pang PhillipChief Medical OfficerJun 17Option Exercise5.1812,50064,68828,277Jun 18 05:00 PM
Pang PhillipChief Medical OfficerJun 17Sale37.2712,500465,81515,777Jun 18 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Option Exercise1.533,8055,8223,805Jun 11 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Sale36.283,805138,0300Jun 11 05:00 PM
Pang PhillipChief Medical OfficerJun 03Option Exercise5.1812,50064,68828,277Jun 04 04:53 PM
Pang PhillipChief Medical OfficerJun 03Sale35.0712,500438,38715,777Jun 04 04:53 PM
Parrish JayChief Business OfficerJun 01Option Exercise1.4975,000111,375297,222Jun 02 09:15 PM
Horn HowardCFOJun 01Sale35.1010,000351,038267,777Jun 02 09:14 PM
Parrish JayChief Business OfficerJun 01Sale35.2275,0002,641,410222,222Jun 02 09:15 PM
Virgin HerbertEVP, Research & CSOMay 26Option Exercise1.533,8055,8223,805May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 26Sale34.083,805129,6740May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 18Option Exercise1.531,7552,6851,755May 19 05:21 PM
Virgin HerbertEVP, Research & CSOMay 18Sale38.001,75566,6900May 19 05:21 PM
Virgin HerbertEVP, Research & CSOMay 14Option Exercise1.533,8055,8223,805May 15 07:48 PM
Parrish JayChief Business OfficerMay 14Option Exercise1.4975,000111,375297,222May 15 07:18 PM
Parrish JayChief Business OfficerMay 14Sale30.0575,0002,253,885222,222May 15 07:18 PM
Virgin HerbertEVP, Research & CSOMay 14Sale30.073,805114,4180May 15 07:48 PM
MORE ROBERT JDirectorMay 01Sale28.0018,458516,85371,534May 05 05:55 PM
Pang PhillipChief Medical OfficerApr 17Option Exercise0.868,0006,84015,777Apr 20 08:20 PM
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E198.39 EPS (ttm)0.47 Insider Own1.30% Shs Outstand61.42M Perf Week-15.64%
Market Cap6.33B Forward P/E- EPS next Y-5.08 Insider Trans-40.37% Shs Float60.43M Perf Month11.21%
Income19.60M PEG- EPS next Q-1.19 Inst Own77.30% Short Float7.96% Perf Quarter0.58%
Sales289.10M P/S21.89 EPS this Y134.10% Inst Trans33.78% Short Ratio5.02 Perf Half Y68.45%
Book/sh14.83 P/B6.25 EPS next Y-5.20% ROA2.00% Target Price96.20 Perf Year132.96%
Cash/sh13.84 P/C6.69 EPS next 5Y- ROE2.40% 52W Range32.30 - 111.90 Perf YTD52.12%
Dividend- P/FCF139.67 EPS past 5Y54.00% ROI4.90% 52W High-17.20% Beta2.29
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low186.84% ATR6.33
Employees304 Current Ratio13.00 Sales Q/Q-86.20% Oper. Margin- RSI (14)48.29 Volatility6.79% 5.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.50% Profit Margin6.80% Rel Volume1.19 Prev Close90.16
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume957.56K Price92.65
Recom2.20 SMA20-1.20% SMA502.58% SMA20034.28% Volume1,141,005 Change2.76%
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
Oct-24-20 08:55AM  
Oct-22-20 05:41PM  
01:11PM  
11:22AM  
Oct-21-20 05:58PM  
04:26PM  
12:19PM  
10:02AM  
08:04AM  
07:00AM  
Oct-16-20 12:12PM  
Oct-15-20 11:18AM  
Oct-12-20 09:45AM  
Oct-09-20 10:14AM  
Oct-08-20 01:31PM  
Oct-07-20 06:05PM  
10:04AM  
09:26AM  
Oct-05-20 02:23PM  
12:28PM  
Sep-30-20 06:45AM  
Sep-29-20 08:00AM  
Sep-24-20 06:04AM  
Sep-23-20 11:03AM  
Sep-22-20 09:00AM  
Sep-15-20 11:00AM  
Sep-14-20 07:20AM  
Sep-10-20 06:55AM  
Sep-09-20 05:26PM  
07:04AM  
Sep-03-20 08:00AM  
Aug-26-20 11:30AM  
Aug-20-20 08:33AM  
Aug-18-20 11:41AM  
Jul-30-20 08:00AM  
Jul-29-20 06:53AM  
Jul-28-20 03:53AM  
Jul-27-20 06:15PM  
05:01PM  
04:30PM  
12:31PM  
10:18AM  
Jul-26-20 08:10AM  
Jul-25-20 11:52AM  
06:45AM  
Jul-21-20 07:07AM  
Jul-17-20 10:11AM  
Jul-15-20 03:13PM  
Jul-13-20 10:53AM  
Jul-08-20 01:35PM  
Jul-07-20 10:00AM  
Jul-02-20 08:43AM  
Jun-30-20 09:30PM  
Jun-29-20 04:01PM  
12:47PM  
10:50AM  
Jun-26-20 08:20AM  
Jun-25-20 08:00AM  
Jun-20-20 09:48AM  
Jun-16-20 06:30AM  
Jun-14-20 06:00AM  
Jun-12-20 02:12PM  
02:30AM  
Jun-05-20 09:35AM  
Jun-03-20 07:54AM  
07:02AM  
Jun-01-20 11:46AM  
May-28-20 11:31AM  
May-26-20 08:30AM  
May-19-20 05:09AM  
May-18-20 06:32PM  
May-16-20 10:00AM  
May-15-20 08:30AM  
May-14-20 09:02AM  
07:10AM  
May-12-20 03:40PM  
May-11-20 05:19PM  
09:00AM  
May-07-20 08:00AM  
Apr-30-20 06:27AM  
Apr-28-20 07:45PM  
04:45PM  
Apr-27-20 12:31PM  
12:00PM  
Apr-24-20 11:41AM  
Apr-18-20 09:56AM  
Apr-03-20 06:34PM  
Mar-27-20 10:47AM  
Mar-23-20 05:50PM  
Mar-10-20 05:50PM  
Mar-02-20 01:03AM  
Feb-26-20 04:05PM  
Feb-19-20 07:59AM  
Feb-13-20 08:05AM  
Feb-12-20 06:55PM  
05:50PM  
04:05PM  
Feb-11-20 02:26PM  
Feb-06-20 05:45PM  
Feb-04-20 02:56PM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novak RodgerPresidentOct 09Option Exercise14.432,76239,856650,769Oct 13 04:44 PM
Novak RodgerPresidentOct 09Sale100.002,762276,200648,007Oct 13 04:44 PM
Novak RodgerPresidentOct 08Option Exercise14.4322,238320,894670,245Oct 13 04:44 PM
Novak RodgerPresidentOct 08Sale100.0022,2382,223,800648,007Oct 13 04:44 PM
Bolzon Bradley J PhDDirectorSep 18Sale86.873,035263,636518,190Sep 22 08:10 PM
Bolzon Bradley J PhDDirectorSep 16Sale86.988,965779,777521,225Sep 18 04:30 PM
Bolzon Bradley J PhDDirectorSep 14Sale84.891,15598,045530,190Sep 16 08:00 PM
Bolzon Bradley J PhDDirectorSep 10Sale85.3622,8451,949,996531,345Sep 11 09:49 PM
Novak RodgerPresidentSep 01Option Exercise14.3625,000359,059673,007Sep 03 04:44 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Option Exercise17.7512,000213,00012,410Sep 03 04:46 PM
Bolzon Bradley J PhDDirectorSep 01Option Exercise25.2360,0001,513,95060,000Sep 03 09:21 PM
Bolzon Bradley J PhDDirectorSep 01Sale92.5160,0005,550,6440Sep 03 09:21 PM
Novak RodgerPresidentSep 01Sale92.6225,0002,315,578648,007Sep 03 04:44 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Sale92.2612,0001,107,068410Sep 03 04:46 PM
Novak RodgerPresidentAug 19Option Exercise14.0025,000350,000673,007Aug 21 04:11 PM
Novak RodgerPresidentAug 19Sale100.0025,0002,500,000648,007Aug 21 04:11 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Option Exercise17.7512,000213,00012,410Aug 05 04:20 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Sale86.7412,0001,040,919410Aug 05 04:20 PM
Novak RodgerPresidentJul 07Option Exercise11.2825,000281,907673,007Jul 09 04:00 PM
Novak RodgerPresidentJul 07Sale90.0025,0002,250,000648,007Jul 09 04:00 PM
Bolzon Bradley J PhDDirectorJul 06Sale82.3920,0001,647,730554,190Jul 08 04:00 PM
Novak RodgerPresidentJul 01Sale80.0050,0004,000,000648,007Jul 06 04:14 PM
Klein Lawrence OttoCBO & COOJun 25Option Exercise12.574,91261,74424,912Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 25Sale75.184,912369,27220,000Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Option Exercise8.5865,088558,70758,666Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Sale75.9365,0884,942,29220,000Jun 26 04:33 PM
Novak RodgerPresidentJun 23Sale75.0050,0003,750,000698,007Jun 25 04:28 PM
Bolzon Bradley J PhDDirectorJun 23Sale75.3510,000753,453574,190Jun 24 07:02 PM
Ho Tony WExecutive VP, Head of R&DJun 23Sale75.206,929521,06133,747Jun 24 05:58 PM
Ho Tony WExecutive VP, Head of R&DJun 22Sale70.1422916,06240,676Jun 24 05:58 PM
Bolzon Bradley J PhDDirectorJun 22Sale72.5110,000725,069584,190Jun 24 07:02 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8117,27531,268188,801Jun 03 05:32 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale64.6817,2751,117,266171,526Jun 03 05:32 PM
Ho Tony WExecutive VP, Head of R&DMay 26Sale70.146,100427,85440,905May 27 04:32 PM
Novak RodgerPresidentMay 26Sale70.2736,6162,573,006748,007May 27 04:34 PM
Novak RodgerPresidentMay 22Sale70.0113,384937,014784,623May 27 04:34 PM
Ho Tony WExecutive VP, Head of R&DMay 22Sale70.0560042,03047,005May 27 04:32 PM
Kulkarni SamarthChief Executive OfficerMay 20Option Exercise1.8110,69319,354182,219May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 20Sale65.2810,693698,039171,526May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Option Exercise1.814,3077,796175,833May 21 04:35 PM
Novak RodgerPresidentMay 19Sale65.0050,0003,250,000798,007May 21 04:37 PM
Kulkarni SamarthChief Executive OfficerMay 19Sale65.164,307280,644171,526May 21 04:35 PM
Klein Lawrence OttoCBO & COOMay 11Option Exercise5.8625,000146,50045,000May 13 04:38 PM
Klein Lawrence OttoCBO & COOMay 11Sale60.4025,0001,509,97120,000May 13 04:38 PM
Kulkarni SamarthChief Executive OfficerDec 16Option Exercise1.818,00014,480172,320Dec 18 04:05 PM
Novak RodgerPresidentNov 19Option Exercise14.4333,618485,10833,618Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 19Option Exercise5.597,50041,9257,500Nov 21 04:07 PM
Novak RodgerPresidentNov 19Sale70.0033,6182,353,2600Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 19Sale62.007,500465,0000Nov 21 04:07 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4128,2551,904,783596,741Nov 21 07:53 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4113,745926,6050Nov 21 07:53 PM
CAGNONI PABLO JDirectorNov 12Option Exercise5.597,50041,9257,500Nov 13 04:30 PM
CAGNONI PABLO JDirectorNov 12Sale55.007,500412,5000Nov 13 04:30 PM
CAGNONI PABLO JDirectorOct 30Option Exercise5.597,50041,9257,500Nov 01 06:35 PM
CAGNONI PABLO JDirectorOct 30Sale52.007,500390,0000Nov 01 06:35 PM
Bolzon Bradley J PhDDirectorOct 30Sale51.8921,0001,089,67513,745Nov 01 06:34 PM
MRNA Moderna, Inc. daily Stock Chart
MRNA [NASD]
Moderna, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own2.50% Shs Outstand380.53M Perf Week-4.61%
Market Cap27.95B Forward P/E26.27 EPS next Y2.69 Insider Trans-31.37% Shs Float354.49M Perf Month8.22%
Income-487.30M PEG- EPS next Q-0.43 Inst Own55.60% Short Float8.53% Perf Quarter-11.74%
Sales105.80M P/S264.20 EPS this Y-27.10% Inst Trans-0.02% Short Ratio2.51 Perf Half Y46.78%
Book/sh7.74 P/B9.11 EPS next Y283.60% ROA-22.30% Target Price92.54 Perf Year325.14%
Cash/sh6.86 P/C10.29 EPS next 5Y16.80% ROE-27.80% 52W Range15.52 - 95.21 Perf YTD260.58%
Dividend- P/FCF- EPS past 5Y- ROI-44.90% 52W High-25.92% Beta-
Dividend %- Quick Ratio17.30 Sales past 5Y- Gross Margin- 52W Low354.45% ATR3.46
Employees830 Current Ratio17.30 Sales Q/Q406.90% Oper. Margin- RSI (14)47.54 Volatility5.00% 4.64%
OptionableYes Debt/Eq0.02 EPS Q/Q25.20% Profit Margin- Rel Volume0.31 Prev Close70.84
ShortableYes LT Debt/Eq0.02 EarningsOct 29 BMO Payout- Avg Volume12.07M Price70.53
Recom2.10 SMA20-2.22% SMA503.36% SMA20035.53% Volume3,723,323 Change-0.44%
Sep-08-20Downgrade SVB Leerink Mkt Perform → Underperform $58 → $41
Jul-23-20Initiated SVB Leerink Mkt Perform
Jul-20-20Downgrade JP Morgan Overweight → Neutral $89
Jul-13-20Initiated Jefferies Buy $90
Jun-30-20Initiated Argus Buy $80
Jun-08-20Initiated Barclays Overweight $68
Apr-30-20Initiated BMO Capital Markets Outperform $83
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $32
Dec-03-19Resumed BofA/Merrill Buy
Oct-25-19Initiated ROTH Capital Buy $24
Apr-05-19Initiated Chardan Capital Markets Buy $40
Oct-25-20 06:14AM  
Oct-24-20 08:10AM  
06:55AM  
06:02AM  
Oct-23-20 07:17PM  
05:45PM  
04:33PM  
04:25PM  
04:06PM  
03:30PM  
03:04PM  
11:33AM  
10:52AM  
09:59AM  
09:44AM  
07:07AM  
06:30AM  
06:08AM  
Oct-22-20 06:24PM  
06:15PM  
04:51PM  
04:38PM  
04:28PM  
04:25PM  
03:37PM  
03:34PM  
03:15PM  
01:59PM  
01:43PM  
12:33PM  
12:04PM  
10:34AM  
10:19AM  
09:47AM  
08:50AM  
07:30AM  
Oct-21-20 05:31PM  
04:34PM  
04:25PM  
12:05PM  
12:00PM  
09:00AM  
06:09AM  
06:00AM  
Oct-20-20 05:00PM  
04:27PM  
04:25PM  
03:49PM  
02:46PM  
02:11PM  
12:15PM  
11:17AM  
10:49AM  
10:12AM  
09:40AM  
09:10AM  
07:08AM  
01:06AM  
Oct-19-20 04:32PM  
04:25PM  
02:17PM  
10:00AM  
Oct-17-20 07:40AM  
07:07AM  
06:11AM  
Oct-16-20 04:57PM  
04:25PM  
03:56PM  
03:45PM  
03:38PM  
03:36PM  
03:24PM  
01:53PM  
01:45PM  
01:01PM  
12:12PM  
10:47AM  
09:57AM  
Oct-15-20 05:45PM  
04:31PM  
04:26PM  
04:23PM  
04:15PM  
11:59AM  
11:44AM  
11:31AM  
09:41AM  
Oct-14-20 08:04PM  
04:44PM  
04:29PM  
04:27PM  
04:22PM  
06:08AM  
03:57AM  
Oct-13-20 06:29PM  
04:31PM  
04:21PM  
04:18PM  
03:56PM  
03:30PM  
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bancel StephaneChief Executive OfficerOct 22Sale68.5810,000685,8007,704,880Oct 23 04:30 PM
HENDERSON LORI M.General Counsel and SecretaryOct 21Option Exercise14.8532,000475,20032,681Oct 23 04:32 PM
Bancel StephaneChief Executive OfficerOct 21Sale71.319,000641,7906,614,868Oct 23 04:30 PM
HENDERSON LORI M.General Counsel and SecretaryOct 21Sale70.1632,0002,245,158681Oct 23 04:32 PM
Bancel StephaneChief Executive OfficerOct 20Sale72.058,455609,1839,085,941Oct 21 04:04 PM
Zaks Tal ZviChief Medical OfficerOct 19Option Exercise16.8415,000252,55015,000Oct 20 05:26 PM
Zaks Tal ZviChief Medical OfficerOct 19Sale71.9415,0001,079,0250Oct 20 05:26 PM
Bancel StephaneChief Executive OfficerOct 16Sale75.0211,046828,618353,488Oct 20 05:24 PM
Bancel StephaneChief Executive OfficerOct 15Sale75.4810,000754,8007,714,880Oct 16 04:45 PM
Bancel StephaneChief Executive OfficerOct 14Sale79.819,000718,2906,624,868Oct 16 04:45 PM
Hoge StephenPresidentOct 13Option Exercise0.9910,0009,9001,931,530Oct 14 04:15 PM
Hoge StephenPresidentOct 13Sale76.6315,0001,149,4121,916,530Oct 14 04:15 PM
Zaks Tal ZviChief Medical OfficerOct 12Option Exercise16.8415,000252,55015,000Oct 13 05:56 PM
Bancel StephaneChief Executive OfficerOct 12Sale73.618,219605,0019,094,396Oct 13 04:13 PM
Zaks Tal ZviChief Medical OfficerOct 12Sale74.4715,0001,117,0490Oct 13 05:56 PM
Hoge StephenPresidentOct 12Sale74.465,000372,2761,921,530Oct 14 04:15 PM
Bancel StephaneChief Executive OfficerOct 09Sale72.9911,046806,259364,534Oct 13 04:13 PM
Bancel StephaneChief Executive OfficerOct 08Sale73.5010,000735,0007,724,880Oct 09 04:10 PM
Bancel StephaneChief Executive OfficerOct 07Sale71.239,000641,0706,634,868Oct 09 04:10 PM
Hoge StephenPresidentOct 05Option Exercise0.9910,0009,9001,936,530Oct 06 04:45 PM
Zaks Tal ZviChief Medical OfficerOct 05Option Exercise16.8415,000252,55015,000Oct 06 04:51 PM
Hoge StephenPresidentOct 05Sale69.5010,000695,0001,926,530Oct 06 04:45 PM
Zaks Tal ZviChief Medical OfficerOct 05Sale70.2415,0001,053,6450Oct 06 04:51 PM
Hoge StephenPresidentOct 02Option Exercise0.9910,0009,9001,936,530Oct 06 04:45 PM
Bancel StephaneChief Executive OfficerOct 02Sale70.6411,046780,251375,580Oct 06 04:36 PM
Hoge StephenPresidentOct 02Sale67.8610,000678,6001,926,530Oct 06 04:45 PM
Bancel StephaneChief Executive OfficerOct 01Sale69.5718,4811,285,7237,734,880Oct 02 04:52 PM
Bancel StephaneChief Executive OfficerSep 30Sale72.729,000654,4806,644,868Oct 02 04:52 PM
Zaks Tal ZviChief Medical OfficerSep 28Option Exercise19.8917,197342,13317,197Sep 29 04:20 PM
Zaks Tal ZviChief Medical OfficerSep 28Sale70.2817,1971,208,5490Sep 29 04:20 PM
Bancel StephaneChief Executive OfficerSep 25Sale68.4911,046756,519386,626Sep 29 04:18 PM
Bancel StephaneChief Executive OfficerSep 24Sale65.5010,000655,0007,744,880Sep 25 04:12 PM
Hoge StephenPresidentSep 24Sale65.195,000325,9501,926,530Sep 25 04:19 PM
Hoge StephenPresidentSep 23Option Exercise0.9910,0009,9001,946,530Sep 25 04:19 PM
Bancel StephaneChief Executive OfficerSep 23Sale67.999,000611,9106,654,868Sep 25 04:12 PM
Hoge StephenPresidentSep 23Sale67.2215,0001,008,3611,931,530Sep 25 04:19 PM
Zaks Tal ZviChief Medical OfficerSep 21Option Exercise20.0420,000400,80020,000Sep 22 05:11 PM